NICE

• 9th Dec 2024

  Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

• 2nd Sep 2024

  A case study of the challenges of demonstrating cost-effectiveness in under-served patient populations: lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer’s disease

• 17th Jun 2024

  Identifying value elements of advanced therapy medicinal products: An opportunistic review of stakeholder responses submitted to NICE as part of reimbursement decision making